ROTH to Host 3rd Annual Healthcare Opportunities Conference in New York City

ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City By Investing.com

NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (ROTH), www.roth.com, is pleased to announce it will host the 3rd Annual Roth Healthcare Opportunities Conference on October 9, 2024, at the Metropolitan Club, New York City, NY. The highly anticipated Annual ROTH Healthcare Opportunities Conference will host C-suite executives from both innovative public and private healthcare companies, as well as marquee institutional investors and sector specialists seeking new opportunities. Participating companies will represent key industry subsectors such as Biotechnology, Brain Disorders, Medical Technologies, Oncology Therapeutics and Pharmaceuticals. The conference will commence with a Breakfast Panel titled "Opportunities and Challenges When Small Names Go After Blockbuster Indications." During this session, industry experts will share unique perspectives on the challenges and opportunities faced by smaller companies targeting blockbuster therapeutic indications. This exclusive, invite-only event will feature 1x1/small group meetings between company executives and ROTH's institutional clients. These 25-minute meetings offer a valuable opportunity for participants to engage in deep discussions about company roadmaps, explore synergies, understand investment strategies, and lay the groundwork for potential collaborations. Attendees will have the opportunity to attend four Lunch Panel Discussions covering cutting-edge topics in healthcare innovation: To facilitate maximum engagement and discovery, these sessions will be moderated by ROTH's senior Healthcare research team, including Jonathan Aschoff, Ph.D., Jason Wittes, Boobalan Pachaiyappan, Ph.D., and Benjamin E. Paluch, Ph.D. The single-day event is designed to optimize business efficiency, offering attendees high-powered networking opportunities, access to educational content, and pathways to develop partnerships and investment opportunities. James Antonopoulos, Managing Director, Head of Healthcare Investment Banking at ROTH, stated, Demand for healthcare innovation has been surging, both in the public and private sectors. The shift is being driven by multiple factors such as changing demographics, advancements in big data and artificial intelligence, and the introduction of new therapeutic and digital solutions. Our conference provides a unique platform for deal discovery, expanding market reach, and forming high-potential partnerships. Jonathan Aschoff, Ph.D., Managing Director, Senior Research Analyst, Biotechnology at ROTH, added, "We believe that the investment environment is finally beginning to improve for smaller cap healthcare companies, especially with interest rates beginning to decrease and the expectation of further near-term decreases. Regardless of market sentiment, companies developing value-added therapies will almost always attract the attention of larger, deep-pocketed healthcare companies that need a pipeline, which almost always provides for a highly favorable investor exit. We look forward to providing access to management through disease-focused panel discussions and individual meetings. At the close of the conference, all attendees are invited to a Cocktail Reception, offering a relaxed environment to foster rapport and build lasting relationships. The conference is exclusively for ROTH's institutional clients and is by invitation only. Prospective attendees are encouraged to contact their ROTH sales representative or email registration@roth.com to express interest and confirm participation. Since 2010, ROTH has been involved in over 600 transactions for its Healthcare clients, with a total transaction value of over $25.1 Billion. (Source: Roth 10/01/2024) Participating Companies at the time of this release include: List as of 10/01/2024 " subject to change For b2i company profiles " https://b2idigital.com/3rd-annual-roth-healthcare-opportunities-conference Thank you to the event sponsors: Pryor Cashman NSI Insurance Group B2I Digital, Inc. IBN (InvestorBrandNetwork) NGO Sustainability Inc. About ROTH ROTH is a relationship-driven investment bank focused on serving growth companies and their investors. Our full-service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, ROTH is a privately held, employee-owned organization and maintains offices throughout the U.S. For more information, please visit www.roth.com.

ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City

NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC ("ROTH"), www.roth.com, is pleased to announce it will host the 3rd Annual Roth Healthcare Opportunities Conference on October 9, 2024, at the Metropolitan Club, New York City, NY. The highly anticipated Annual ROTH Healthcare Opportunities Conference will host C-suite executives from both innovative public and private healthcare companies, as well as marquee institutional investors and sector specialists seeking new opportunities. Participating companies will represent key industry subsectors such as Biotechnology, Brain Disorders, Medical Technologies, Oncology Therapeutics and Pharmaceuticals. The conference will commence with a Breakfast Panel titled "Opportunities and Challenges When Small Names Go After Blockbuster Indications." During this session, industry experts will share unique perspectives on the challenges and opportunities faced by smaller companies targeting blockbuster therapeutic indications. This exclusive, invite-only event will feature 1x1/small group meetings between company executives and ROTH's institutional clients. These 25-minute meetings offer a valuable opportunity for participants to engage in deep discussions about company roadmaps, explore synergies, understand investment strategies, and lay the groundwork for potential collaborations. Attendees will have the opportunity to attend four Lunch Panel Discussions covering cutting-edge topics in healthcare innovation: Emerging Frontiers in NeuroscienceInnovative Therapies for Solid TumorsInnovative Therapies for Liquid TumorsOncolytic and Non-Oncolytic Viral Immunotherapies To facilitate maximum engagement and discovery, these sessions will be moderated by ROTH's senior Healthcare research team, including Jonathan Aschoff, Ph.D., Jason Wittes, Boobalan Pachaiyappan, Ph.D., and Benjamin E. Paluch, Ph.D. The single-day event is designed to optimize business efficiency, offering attendees high-powered networking opportunities, access to educational content, and pathways to develop partnerships and investment opportunities. James Antonopoulos, Managing Director, Head of Healthcare Investment Banking at ROTH, stated, "Demand for healthcare innovation has been surging, both in the public and private sectors. The shift is being driven by multiple factors such as changing demographics, advancements in big data and artificial intelligence, and the introduction of new therapeutic and digital solutions. Our conference provides a unique platform for deal discovery, expanding market reach, and forming high-potential partnerships." Jonathan Aschoff, Ph.D., Managing Director, Senior Research Analyst, Biotechnology at ROTH, added, "We believe that the investment environment is finally beginning to improve for smaller cap healthcare companies, especially with interest rates beginning to decrease and the expectation of further near-term decreases. Regardless of market sentiment, companies developing value-added therapies will almost always attract the attention of larger, deep-pocketed healthcare companies that need a pipeline, which almost always provides for a highly favorable investor exit. We look forward to providing access to management through disease-focused panel discussions and individual meetings." At the close of the conference, all attendees are invited to a Cocktail Reception, offering a relaxed environment to foster rapport and build lasting relationships. The conference is exclusively for ROTH's institutional clients and is by invitation only. Prospective attendees are encouraged to contact their ROTH sales representative or email registration@roth.com to express interest and confirm participation. Since 2010, ROTH has been involved in over 600 transactions for its Healthcare clients, with a total transaction value of over $25.1 Billion. (Source: Roth 10/01/2024) AGENDA WEDNESDAY | OCTOBER 9, 2024 07:00am - 9:00amRegistration and Breakfast08:00am - 8:40amBreakfast Panel - Opportunities and Challenges When Small Names Go After Blockbuster Indications 09:00am - 5:00pm1-on-1 meetings (No 1-on-1 meetings during Panels)11:45am - 12:25pmLunch Panel 1 - Emerging Frontiers in Neuroscience12:30pm - 1:10pmLunch Panel 2 - Innovative Therapies for Solid Tumors1:15pm - 1:55pmLunch Panel 3 - Innovative Therapies for Liquid Tumors2:00pm - 2:40pm Lunch Panel 4 - Oncolytic and Non-Oncolytic Viral Immunotherapies5:00pm - 6:00pmCocktail Reception All times are listed in Eastern Time (ET) VENUE Metropolitan Club 1 East 60th St. off 5th Ave. New York, NY 10022 Participating Companies at the time of this release include: Company NameMobile Friendly URLAllurion Technologies, Inc. (ALUR)https://www.allurion.com/enBaird Medical (BDMD)https://bairdmed.com/pages/about-usBeyond Air, Inc. (XAIR)https://www.beyondair.net/Biofrontera Inc. (BFRI)https://www.biofrontera-us.com/BioRestorative Therapies, Inc. (BRTX)https://www.biorestorative.com/Candel Therapeutics, Inc. (CADL)https://www.candeltx.com/Cardiol Therapeutics Inc. (CRDL)https://www.cardiolrx.com/Cellectar Biosciences, Inc. (CLRB)https://www.cellectar.com/CervoMed Inc. (CRVO)https://www.cervomed.com/Chemomab Therapeutics Ltd. (CMMB)https://www.chemomab.com/Cingulate Inc. (CING)https://www.cingulate.com/Cognition Therapeutics, Inc. (CGTX)https://cogrx.com/about-us/Fortress Biotech, Inc. (FBIO)https://www.fortressbiotech.com/Gain Therapeutics, Inc. (GANX)https://www.gaintherapeutics.com/GeoVax Labs, Inc. (GOVX)https://www.geovax.com/GT Biopharma, Inc. (GTBP)https://www.gtbiopharma.com/iRadimed Corp. (IRMD)https://www.iradimed.com/Journey Medical Corp. (DERM)https://journeymedicalcorp.com/Longeveron Inc (LGVN)https://longeveron.com/Moleculin Biotech, Inc. (MBRX)https://moleculin.com/Nuvectis Pharma, Inc. (NVCT)https://nuvectis.com/Nuwellis, Inc. (NUWE)https://ir.nuwellis.com/Orthofix Medical Inc. (OFIX)https://orthofix.com/Ovid Therapeutics Inc. (OVID)https://ovidrx.com/Replimune Group, Inc. (REPL)https://replimune.com/Revelation Biosciences, Inc. (REVB)https://www.revbiosciences.com/Reviva Pharmaceuticals Holdings, Inc. (RVPH)https://revivapharma.com/Sensus Healthcare, Inc. (SRTS)https://sensushealthcare.com/Stereotaxis, Inc. (STXS)https://ir.stereotaxis.com/TFF Pharmaceuticals, Inc. (TFFP)https://tffpharma.com/TriSalus Life Sciences, Inc. (TLSI)https://trisaluslifesci.com/ List as of 10/01/2024 - subject to change For b2i company profiles - https://b2idigital.com/3rd-annual-roth-healthcare-opportunities-conference Thank you to the event sponsors: Pryor Cashman NSI Insurance Group B2I Digital, Inc. IBN (InvestorBrandNetwork) NGO Sustainability Inc. About ROTH ROTH is a relationship-driven investment bank focused on serving growth companies and their investors. Our full-service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, ROTH is a privately held, employee-owned organization and maintains offices throughout the U.S. For more information, please visit www.roth.com. Investor Contact: ROTH Isabel Mattson-Pain Managing Director, Chief Marketing Officer 949.720.7117, imattson-pain@roth.com ROTH - Member FINRA/SIPC - www.roth.com IBN Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717, Editor@InvestorBrandNetwork.com Market News and Data brought to you by Benzinga APIs